Development of new fibrinolytic agents

Current Pharmaceutical Design
Shigeru Ueshima, Osamu Matsuo

Abstract

Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic, which removes the thrombus from the circulation. The fibrinolytic system plays an important role in the dissolution of fibrin, which is the main component of thrombus. So that, the balance between the coagulation and fibrinolytic system regulates the formation of thrombus. Now, the new agents that activate the fibrinolytic system have been clinically applied for the thrombolytic therapy. The main factor in fibrinolytic system is the plasmin, which is activated from the plasminogen by the plasminogen activator (PA). The plasminogen activator is mainly used for the thrombolytic therapy. There are two types of PA. One is the non fibrin-specific PA such as streptokinase (SK) and two-chain urokinase-type PA (tcu-PA, urokinase), and another is the fibrin-specific PA such as tissue-type PA (t-PA) and single-chain urokinase-type PA (scu-PA). Recently, some derivatives of t-PA have been developed to obtain the longer half-life than native t-PA and...Continue Reading

Citations

Feb 18, 2010·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Chikako IshidaOsamu Matsuo
Jul 11, 2012·The Journal of Pharmacy and Pharmacology·Martin Flemmig, Matthias F Melzig
Mar 17, 2011·The Biochemical Journal·Charles S CraikEdwin L Madison
Jun 10, 2014·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Zhang KeYu-fei Fun
Nov 5, 2019·Molecular Biology Reports·Reza NedaeiniaMaryam Ranjbar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.